MX368288B - Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple. - Google Patents

Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.

Info

Publication number
MX368288B
MX368288B MX2015003589A MX2015003589A MX368288B MX 368288 B MX368288 B MX 368288B MX 2015003589 A MX2015003589 A MX 2015003589A MX 2015003589 A MX2015003589 A MX 2015003589A MX 368288 B MX368288 B MX 368288B
Authority
MX
Mexico
Prior art keywords
combinations
melphalan
antibody
present disclosure
disclosure describes
Prior art date
Application number
MX2015003589A
Other languages
English (en)
Other versions
MX2015003589A (es
Inventor
Endell Jan
Rojkjaer Lisa
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2015003589A publication Critical patent/MX2015003589A/es
Publication of MX368288B publication Critical patent/MX368288B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

La presente invención se refiere a una combinación sinérgica de un anticuerpo específico para CD38 que comprende un HCDR1 de secuencia (ID SEC NO: 1) un HCDR2 de secuencia (ID SEC NO: 2), un HCDR3 de secuencia (ID SEC NO: 3), un LCDR1 de secuencia (ID SEC NO:4), un LCDR2 de secuencia (ID SEC NO: 5), y un LCDR3 de secuencia (ID SEC NO: 6) y melfalán para usarse en el tratamiento de mieloma múltiple.
MX2015003589A 2012-09-25 2013-09-24 Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple. MX368288B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705172P 2012-09-25 2012-09-25
US201361774595P 2013-03-08 2013-03-08
PCT/EP2013/069858 WO2014048921A1 (en) 2012-09-25 2013-09-24 Combinations and uses thereof

Publications (2)

Publication Number Publication Date
MX2015003589A MX2015003589A (es) 2015-08-12
MX368288B true MX368288B (es) 2019-09-27

Family

ID=49237209

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003589A MX368288B (es) 2012-09-25 2013-09-24 Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.

Country Status (23)

Country Link
US (1) US9579378B2 (es)
EP (1) EP2900232B1 (es)
JP (1) JP6426093B2 (es)
KR (1) KR102171669B1 (es)
CN (1) CN104684552B (es)
AU (1) AU2013322806C1 (es)
BR (1) BR112015006731A2 (es)
CA (1) CA2885792C (es)
DK (1) DK2900232T3 (es)
ES (1) ES2658953T3 (es)
HK (1) HK1210949A1 (es)
HR (1) HRP20171964T1 (es)
HU (1) HUE036518T2 (es)
IL (1) IL237926B (es)
LT (1) LT2900232T (es)
MX (1) MX368288B (es)
NZ (1) NZ706147A (es)
PL (1) PL2900232T3 (es)
PT (1) PT2900232T (es)
RU (1) RU2650618C2 (es)
SG (1) SG11201502163QA (es)
WO (1) WO2014048921A1 (es)
ZA (1) ZA201501980B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1945671A2 (en) 2005-10-12 2008-07-23 MorphoSys AG Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2016040294A2 (en) * 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
NZ732753A (en) 2014-12-04 2024-08-30 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
KR102602754B1 (ko) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
ES2890783T3 (es) 2015-06-22 2022-01-24 Janssen Biotech Inc Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-CD38 e inhibidores de survivina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN108472369A (zh) 2015-11-03 2018-08-31 詹森生物科技公司 抗cd38抗体的皮下制剂及其用途
CA3016098A1 (en) * 2016-03-04 2017-09-08 Morphosys Ag Clinical assessment of m-protein response in multiple myeloma
EP3421494A1 (en) * 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
CA2329940A1 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
ES2541489T3 (es) 2004-02-06 2015-07-21 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
CN107033243B (zh) 2005-03-23 2020-12-15 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
US20090123950A1 (en) 2005-05-24 2009-05-14 Morphosys Ag Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
EP1945671A2 (en) * 2005-10-12 2008-07-23 MorphoSys AG Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
JP6093696B2 (ja) * 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
ES2617446T3 (es) * 2010-09-27 2017-06-19 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US20140221319A1 (en) 2011-06-29 2014-08-07 Mayo Foundation For Medical Education And Research Small Molecule CD38 Inhibitors and Methods of Using Same
IL241407B (en) 2013-03-13 2022-06-01 Univ California Preparations containing antibodies against cd-38 and carfilzomib
PT2992013T (pt) 2013-04-29 2020-03-05 Teva Pharmaceuticals Australia Pty Ltd Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado

Also Published As

Publication number Publication date
AU2013322806B2 (en) 2017-11-30
CN104684552A (zh) 2015-06-03
AU2013322806C1 (en) 2018-03-08
HK1210949A1 (en) 2016-05-13
ZA201501980B (en) 2017-11-29
CN104684552B (zh) 2018-08-07
US20150238603A1 (en) 2015-08-27
WO2014048921A1 (en) 2014-04-03
US9579378B2 (en) 2017-02-28
IL237926A0 (en) 2015-05-31
PL2900232T3 (pl) 2018-05-30
SG11201502163QA (en) 2015-04-29
NZ706147A (en) 2018-10-26
RU2650618C2 (ru) 2018-04-16
KR102171669B1 (ko) 2020-10-30
CA2885792A1 (en) 2014-04-03
KR20150090030A (ko) 2015-08-05
CA2885792C (en) 2021-09-28
RU2015110981A (ru) 2016-11-20
EP2900232B1 (en) 2017-11-15
JP6426093B2 (ja) 2018-11-28
EP2900232A1 (en) 2015-08-05
MX2015003589A (es) 2015-08-12
PT2900232T (pt) 2018-02-09
IL237926B (en) 2020-04-30
HUE036518T2 (hu) 2018-07-30
DK2900232T3 (en) 2018-02-05
AU2013322806A1 (en) 2015-04-09
BR112015006731A2 (pt) 2017-07-04
JP2015530399A (ja) 2015-10-15
HRP20171964T1 (hr) 2018-02-23
LT2900232T (lt) 2018-02-26
ES2658953T3 (es) 2018-03-13

Similar Documents

Publication Publication Date Title
MX368288B (es) Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.
DOP2016000224A (es) Tratamientos combinados con anticuerpos anti-cd38
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
EP4223770A3 (en) Novel fusion molecules and uses thereof
BR112013006769A2 (pt) combinação sinérgica de um anticorpo específico para cd38
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX370649B (es) Proceso para la preparacion de teneligliptina.
IL244043B (en) Antibodies against CSF-1r and their use.
AU357215S (en) Positioning element for construction toy
EP3081248A4 (en) Co-injection member
EP3025527A4 (en) Generating geofences
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
IN2014DN09798A (es)
MX2016008350A (es) Sistema de dos componentes, en particular para formacion de adhesivo.
EP3747444A3 (en) Use of sedoheptulose as a nutritional supplement
MX2015010789A (es) Anticuerpos anti-pcsm.
WO2014093305A3 (en) Micrornas and uses thereof
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
AU5362P (en) Kasumi Bougainvillea hybrid
UY4265Q (es) Automóvil
AU338760S (en) Container

Legal Events

Date Code Title Description
FG Grant or registration